Susan Benton - 01 Apr 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Director
Signature: /s/ Emily J. Johns, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 01 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Apr 2022, 09:16:55 UTC
Previous filing: 05 Jan 2022
Next filing: 15 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Award		+3,395	+12%		32,455	01 Apr 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted shares of common stock in lieu of cash for board services for the first quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $3.24 per share, the closing price of the common stock on March 31, 2022.

Content

The Reporting Person was granted shares of common stock in lieu of cash for board services for the first quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $3.24 per share, the closing price of the common stock on March 31, 2022.